Cormorant Asset Management, LP Olema Pharmaceuticals, Inc. Transaction History

Cormorant Asset Management, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$10.53 - $17.14 $21.6 Million - $35.1 Million	-2,047,964 Reduced 45.46%	2,456,800 $34.5 Million
Q3 2023 Nov 14, 2023	BUY	$8.19 - $12.98 $11.7 Million - $18.5 Million	1,422,764 Added 46.16%	4,504,764 $55.6 Million
Q1 2023 May 15, 2023	BUY	$2.55 - $4.97 $2.55 Million - $4.97 Million	1,000,000 Added 48.03%	3,082,000 $10.7 Million
Q1 2022 May 16, 2022	SELL	$3.89 - $9.43 $341,818 - $828,623	-87,871 Reduced 4.05%	2,082,000 $8.87 Million
Q4 2021 Feb 14, 2022	SELL	$8.75 - $30.71 $7.91 Million - $27.7 Million	-903,614 Reduced 29.4%	2,169,871 $20.3 Million
Q2 2021 Aug 16, 2021	SELL	$21.15 - $36.14 $2.58 Million - $4.41 Million	-122,059 Reduced 3.82%	3,073,485 $86 Million
Q4 2020 Feb 16, 2021	BUY	$37.09 - $54.5 $119 Million - $174 Million	3,195,544 New	3,195,544 $148 Million

136

58.7M

141K

23.1K

Ticker OLMA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,419,600
Market Cap $247M
Description
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, local...

Get notified when there are updates to the investment portfolio of Cormorant Asset Management, LP, based on Form 13F filings with the SEC.

Stay updated on Cormorant Asset Management, LP with notifications on news.